[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oligoprogressive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oligoprogressive":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,68,90,108,132,156,181,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100523866","locally-ablative-therapy-for-oligo-progressive-gastrointestinal-malignancies-livelong-100523866",false,"NCT06101277","Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)","LIVELONG","Inclusion Criteria:\n\n1. Must have one of the following histologically and\u002For biochemically confirmed cancers:\n\n   1. Cohort A: (Cohort removed in protocol version 4.0)\n   2. Cohort B: Small bowel\n   3. Cohort C: Pancreatic and ampullary, colorectal, and appendiceal\n   4. Cohort D: (Cohort removed in protocol version 4.0)\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\u002F interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.",[26,27,28,29,30,31,32,33],"Small Bowel Cancer","Colorectal Cancer","Appendiceal Cancer","Biliary Cancer","Gall Bladder Cancer","Intrahepatic Cholangiocarcinoma","Extrahepatic Cholangiocarcinoma","Oligoprogressive","RECRUITING","2026-06-30",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2023-10-05",{"date":42,"type":20},"2039-09-15",{"name":44,"class":45},"University of California, Davis","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":24,"conditions":57,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":46},"100523867","locally-ablative-therapy-in-oligo-progressive-genitourinary-tumors-layover-100523867","NCT06101290","Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)","LAYOVER","Inclusion Criteria:\n\n1. Must have one of the following histologically and\u002For biochemically confirmed genitourinary malignancies:\n\n   1. Cohort A: prostate cancer\n   2. Cohort B: urothelial carcinoma\n   3. Cohort C: renal cell carcinoma\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\u002F interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",{"count":55,"type":20},150,[23],[58,33,59,60],"Prostate Cancer","Urothelial Carcinoma","Renal Cell Carcinoma","2026-06-25",{"date":35,"type":38},{"date":64,"type":38},"2023-12-05",{"date":66,"type":20},"2035-01-15",{"name":44,"class":45},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":24,"conditions":78,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":46},"100524050","locally-ablative-therapy-in-oligo-progressive-solid-tumors-valorous-100524050","NCT06103669","Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)","VALOROUS","Inclusion Criteria:\n\n1. Must have one of the following histologically and\u002For biochemically confirmed genitourinary malignancies:\n\n   1. Cohort A: Breast Malignancy\n   2. Cohort B: Gynecological Malignancy\n   3. Cohort C: Head and Neck Malignancies\n   4. Cohort D: Sarcomas\n   5. Cohort E: Other solid malignancy specified in the protocol\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\u002F interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",{"count":76,"type":20},250,[23],[79,33,80,81,82],"Breast Cancer","Head and Neck Cancer","Sarcoma","Other Cancer","2026-06-11",{"date":85,"type":38},"2026-06-15",{"date":40,"type":38},{"date":88,"type":20},"2033-12",{"name":44,"class":45},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":24,"conditions":100,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":46},"100524051","locally-ablative-therapy-for-oligoprogressive-lung-and-thoracic-malignancies-obliterate-100524051","NCT06103682","LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)","OBLITERATE","Inclusion Criteria:\n\n1. Must have one of the following histologically and\u002For biochemically confirmed genitourinary malignancies:\n\n   1. Cohort A: Non-small cell cancer\n   2. Cohort B: Small cell cancer\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\u002F interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",{"count":98,"type":20},100,[23],[101,33,102],"Non-small Cell Lung Cancer","Small-cell Lung Cancer",{"date":85,"type":38},{"date":40,"type":38},{"date":106,"type":20},"2032-01-05",{"name":44,"class":45},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":46},"100437315","phase-2-trial-of-stereotactic-body-radiation-therapy-sbrt-for-oligoprogression-on-immune-checkpoint-inhibitors-ici-in-metastatic-renal-cell-carcinoma-100437315","NCT04974671","Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma","Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\nIn order to be eligible for participation in this trial, the subject must:\n\n1. Be willing and able to provide written informed consent\u002Fassent for the trial\n2. Be ≥ 18 years of age on day of signing informed consent.\n3. Have histologically confirmed renal cell carcinoma with metastatic disease detected on imaging. Biopsy of metastasis is preferred but not required\n4. The subject has a performance status of 0, 1, or 2 on the ECOG Performance Scale\n5. The life expectancy is \\> 6 months\n6. The most recent systemic therapy must be an ICI-containing regimen, delivered for at least 3 months prior to development of oligoprogressive lesions, with the last dose received within 3 months of trial enrollment.\n7. Oligoprogression - defined as documented progression in up to 5 individual lesions with no previous local therapy to those sites using one of the following criteria:\n\n   7.1 RECIST 1.1 7.1.1 At least a 20% increase in the sum of diameters of target lesions (long axis for non-nodal lesions, short axis for nodal lesions), using the previous imaging as a baseline 7.1.2 The sum of all diameters must demonstrate an absolute increase of at least 5 mm 7.1.3 The appearance of at least one new unequivocal lesion 7.2 PERCIST 7.2.1 SUVpeak, normalized to lean body mass (SUL) increase by at least 30% and increase by at least 0.8 SUL of the target lesion 7.2.2 Development of at least one new lesion 7.2.3 Increase in target lesion size by 30% 7.2.4 Unequivocal progression of nontarget lesions 7.3 Progressive enlargement of a known metastasis on 2 consecutive imaging studies at least 2 months apart with a minimum 5 mm increase in size 7.4 Development of a new soft tissue metastatic lesion at least 5 mm in size or any new bone metastasis\n8. There is no restriction on the total number of metastases\n9. Demonstrate adequate organ function as defined in Table 4, all screening labs should be performed within 28 days of protocol treatment\n\n   Table 4 Adequate Organ Function Laboratory Values\n\n   System Laboratory Value\n\n   Hematological\n\n   Absolute neutrophil count (ANC) ≥ 1,500 \u002FmcL Platelets ≥ 75,000 \u002F mcL Hemoglobin ≥ 9 g\u002FdL\n\n   Renal - IF SBRT will be delivered to a lesion in or abutting the kidney\n\n   Serum creatinine OR ≤1.5 X upper limit of normal (ULN) OR Measured or calculated\\* creatinine clearance (GFR can also be used in ≥30 mL\u002Fmin for subject with creatinine place of creatinine or CrCl) levels \\> 1.5 X institutional ULN\n\n   Hepatic - IF SBRT will be delivered to a lesion in or abutting the liver\n\n   Serum total bilirubin ≤ 1.5 X ULN Direct bilirubin Direct bilirubin ≤ ULN for subjects with total bilirubin levels \\> 1.5 ULN AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR\n   * 5 X ULN for subjects with liver metastases\n\n     * Creatinine clearance should be calculated per institutional standard\n10. Able to be treated with SBRT at a Yale radiation oncology facility\n11. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of SBRT. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n12. Female subjects of childbearing must use an effective form of birth control during this study. Acceptable and highly effective birth control methods include intra-uterine hormone releasing system as well as other methods of birth control including consistent use of an approved oral contraceptive (birth control pill), an implantable contraceptive, an injectable contraceptive, a double-barrier method, or true abstinence. Oral, implantable, or injectable contraceptives are only considered effective if used properly and started at least 30 days prior to the screening visit and continue for 120 days after last dose of study drug. (Reference Section 5.7)\n13. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy\n\nExclusion Criteria:\n\nThe subject must be excluded from participating in the trial if the subject\n\n1. Has had radiation therapy within 2 weeks of the first protocol treatment.\n2. Has brain-only oligoprogression. subjects with brain and systemic oligoprogression can still be considered, however treatment of brain metastases will be per standard of care prior to receiving study SBRT.\n3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks of the first protocol treatment. The use of lowdose steroids for management of chronic conditions is allowed (up to 12mg prednisone orally per day or the equivalent).\n4. Has had prior radiation therapy within 2 weeks of the first protocol treatment.\n5. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.\n6. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma\u002Fatopy would be an example of an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Those with a history of hypothyroidism who are now stable on hormone replacement will not be excluded. Those with Sjorgen's syndrome will not be excluded from the study.\n7. Has a history of (non-infectious) pneumonitis that required steroids, current pneumonitis, or underlying lung disease that according to the treating physician makes the patient ineligible.\n8. Has an active infection requiring systemic therapy.\n9. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.\n10. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n11. Has received a live vaccine within 30 days prior to the first protocol treatment.\n12. Has serious medical comorbidities precluding radiotherapy. These include subjects with connective tissue diseases such as lupus or scleroderma, Crohn's disease in subjects where the GI tract will receive radiation\n13. Substantial overlap with a previously treated radiation volume. Prior radiotherapy is allowed as long as the composite plan meets dose constraints",{"count":116,"type":20},30,[118],"PHASE2","This Phase II trial will evaluate progression-free survival after Stereotactic Body Radiation Therapy to oligoprogressive (1-5) lesions in metastatic renal cell carcinoma patients on any immune checkpoint inhibitor-containing regimen with last dose of systemic therapy within 3 months prior to trial enrollment.",[60,121,33,122],"Metastatic Renal Cell Carcinoma","Progression","2025-12-03",{"date":125,"type":38},"2025-12-04",{"date":127,"type":38},"2023-12-22",{"date":129,"type":20},"2028-04-01",{"name":131,"class":45},"Yale University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100462455","phase-2-continue-the-same-systemic-therapy-after-local-ablative-therapy-for-oligo-progression-in-metastatic-breast-cancer---the-cosmo-study-100462455","NCT05301881","COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study","COSMO","Inclusion Criteria:\n\n* Histologically confirmed invasive breast cancer\n* Metastatic breast cancer\n* Oligoprogression defined as one or two distant metastatic lesions, limited to one organ, or the primary tumor or locoregional lymph nodes, increasing ≥20% in size and be larger than 15 mm or if metabolic activity increases (with 20% in SUVmax) on FDG-PET-CT.\n* Systemic treatment can be either endocrine, targeted, chemotherapy or immune-checkpoint blockade\n* Patients should be on systemic therapy for at least six months. Status should be stable disease or partial or complete response for at least 6 months.\n* Oligoprogression has to be detected with radiological imaging comparing the lesion on the same type of imaging modality as has been used at the start of systemic therapy.\n* The radiological imaging that shows progression must be performed within 70days prior to LAT.\n* Bone metastases are classified as progressive if the lytic component of the lesion increases by ≥20% or the FDG-uptake increases by ≥20% on FDG-PET-CT\n* Oligo-progression has to be confirmed with a FDG-PET-CT-scan 5-7 weeks after the initial scan that showed oligoprogression.\n* Lesion(s) must be amenable to resection, radiotherapy or radiofrequency ablation with the intent of local obliteration\n* Age ≥18\n* World Health Organization (WHO) Performance Status 0 or 1\n* Signed written informed consent before patient registration according to ICH\u002FGCP, and national\u002Flocal regulations\n\nExclusion Criteria:\n\n* Having received more than two lines of systemic therapy for MBC If a treatment regimen has been de-escalated without adding other therapies, this is seen as one line of therapy. For example: Pertuzumab\u002Ftrastuzumab+docetaxel followed by pertuzumab\u002Ftrastuzumab will be viewed as one line of systemic therapy.\n* Other malignancy except carcinoma in situ and basal-cell and squamous cell carcinoma of the skin, unless the other malignancy was treated ≥5 years ago with curative intent without the use of chemotherapy or radiation therapy\n* Current pregnancy or breastfeeding. Women of childbearing potential must use adequate contraceptive protection\n* Presence of any medical condition that would place the patient at unusual risk, up to the discretion of the clinician\n* Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule",{"count":140,"type":20},118,[118],"Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included. The local ablative therapy (LAT) may consist of stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, surgery or radiofrequency ablation (RFA).",[144,145,33],"Breast Cancer Invasive","Metastatic Cancer","2025-02-03",{"date":148,"type":38},"2025-02-05",{"date":150,"type":38},"2023-04-17",{"date":152,"type":20},"2040-04-01",{"name":154,"class":45},"The Netherlands Cancer Institute",7,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":164,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":46},"100561042","phase-3-metastasis-directed-therapy-in-oligoprogressive-castration-refractory-prostate-cancer-100561042","NCT06585007","Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer: a Randomized Phase 3 Trial","MEDCARE","Inclusion Criteria:\n\nParticipants eligible for inclusion in this Trial must meet all the following criteria:\n\n* Written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n* Acinar adenocarcinoma (inclusive neuro-endocrine dedifferentiation).\n* Oligoprogressive disease on conventional imagine within a maximum of 6 weeks prior to randomisation defined as: a maximum of 3 extracranial progressive lesions (pre-existing lesions, the development of new lesions, or both) in any organ. Nodal (N1) disease should be measured in the short axis. Nodes more than 1.5 cm in the short axis are considered pathologic and measurable. Oligoprogression on bone scan is defined as the occurrence of maximal 3 new and\u002For progressive lesions. In case of not unambiguously, additional imaging such as diagnostic magnetic resonance imaging (MRI) or dedicated CT-scan should be performed. Visceral disease reported separately (lung, liver, adrenal, or CNS) and is considered measurable if an individual lesions is more than 1 cm longest dimension.\n\nIn case of locally persistent\u002Frecurrent disease, a diagnostic MRI of the prostate (bed) and\u002For biopsy of the site is recommended. There are two different mCRPC patient groups who are eligible for inclusion in the trial:\n\n1. Patients with oligoprogressive disease with pADT only as ongoing treatment (Type 1).\n2. Patients with oligoprogressive disease with pADT +\u002F- second line systemic therapy. This is both the combination of pADT + ARTA as ongoing treatment or patients who had received docetaxel in the past (Type 2).\n\n   * Castration-refractory disease, defined as testosterone level \\\u003C 50 ng\u002FdL.\n   * Prior treatment of the primary tumor by radiotherapy or surgery. If the primary tumor has not been treated previously, this treatment is obligatory within the trial.\n   * WHO performance 0-2\n   * Age \\>= 18 years old\n   * Absence of psychological, sociological, or geographical condition potentially hampering compliance with study protocol.\n   * Patients must be presented at the multidisciplinary board meeting and the inclusion in the trial needs approval by this board.\n\nExclusion Criteria:\n\n* Ductal adenocarcinoma and small-cell prostate cancer.\n* Serum testosterone level \\> 50 ng\u002Fml.\n* Presence of poly-progressive disease, defined as more than 3 progressive lesions on conventional imaging or nodal and\u002For metastatic lesions on conventional imaging\n* Active malignancy other than prostate cancer that could potentially interfere with the interpretation of this trial.\n* Previous treatments (RT, surgery) or comorbidities rendering new treatment with SBRT impossible.\n* Spinal bone lesion that is highly symptomatic, neurologically threatening or at risk of fracture.\n* Patients already treated with radionuclides, cabazitaxel or PARP-inhibitors in the past.\n* Patients with progressive disease while receiving docetaxel.\n* Not able to understand the treatment protocol or sign informed consent.","MALE",{"count":166,"type":20},246,[168],"PHASE3","Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.",[171,33],"Castration-resistant Prostate Cancer","2024-09-04",{"date":174,"type":38},"2024-09-05",{"date":176,"type":38},"2023-12-19",{"date":178,"type":20},"2029-01-20",{"name":180,"class":45},"Universitaire Ziekenhuizen KU Leuven",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":164,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":46},"100426891","stereotactic-ablative-radiation-therapy-for-abiraterone-resistant-oligoprogressive-metastatic-prostate-cancer-100426891","NCT04838899","Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer","Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer During Abiraterone Therapy","Inclusion Criteria:\n\n* ECOG performance status 0-1.\n* Histologic confirmation of prostate adenocarcinoma.\n* Documentation of metastatic, castration-resistant prostate cancer.\n* Patient being treated with abiraterone.\n* Evidence of oligoprogression (according to RECIST \\[V1.1\\] and\u002For Prostate Cancer Working Group criteria \\[PCWG3\\], as applicable), applying any of the following: (i) ≤ 5 metastatic lesions progressing on conventional imaging (≤ 3 progressing metastases in any one organ system) while all other metastases are controlled or responding; (ii) PSA progression only, but in the setting of oligometastases (≤ 5 metastatic lesions seen on imaging, with ≤ 3 metastases in any one organ system); in this setting, all metastases will be irradiated.\n* All metastases of interest amenable to SABR.\n\nExclusion Criteria:\n\n* Patients presenting with unequivocal clinical progression, defined as one of the following: (i) cancer pain requiring the initiation of opioid therapy; (ii) immediate need for cytotoxic chemotherapy as per treating physician's discretion; or (iii) deterioration of performance status to grade ≥ 3 according to ECOG.\n* Evidence of spinal cord compression.\n* Prior malignancy within the past 5 years, excluding non-melanoma skin cancer, and in-situ cancer.",{"count":116,"type":20},[23],"There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases. The latter applies to a situation whereby patients with widespread metastases undergoing systemic therapy present with a solitary or a few metastatic tumors that progress, while all other metastases are stable or responding. The usual practice would be to change systemic therapy at this point, but another approach is to locally ablate the \"rogue\" metastases and continue the same systemic therapy. SABR used in this scenario may delay the need to switch to another line of systemic therapy and improve progression-free survival while patients stay on the same systemic therapy.",[33,192],"Castration-Resistant Prostate Cancer","2024-04-10",{"date":195,"type":38},"2024-04-12",{"date":197,"type":38},"2016-07-16",{"date":199,"type":20},"2026-12-31",{"name":201,"class":45},"Sunnybrook Health Sciences Centre",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":46},"100438472","phase-2-stereotactic-ablative-radiotherapy-for-oligo-progressive-disease-refractory-to-systemic-therapy-in-metastatic-cancer-100438472","NCT04989725","Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer","Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer: A Phase II Randomized Trial","SUPPRESS","Inclusion Criteria:\n\n* Age ≥18 years\n* Biopsy proven HNSCC (oropharynx, oral cavity, nasopharynx, sinonasal, larynx or hypopharynx)\n* Metastatic HNSCC, with pathological or radiological proof of metastasis\n* Ability to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Progressive disease while on systemic treatment (any line), defined as per RECIST criteria 1.1 on CT metrics as a greater than 20% increase in the sum measurement of lesions, non-target unequivocal progressive disease or a new lesion on CT.\n* Oligoprogression to 1-5 extracranial lesions ≤ 5cm and involving ≤ 3 organs. Progression at the primary tumor site should be counted within the total of 5 lesions. For patients with lymph node metastases, each node is counted as one site of metastasis.\n* All sites of disease can, in the opinion of the investigator, be safely treated and targetable with SABR (taking into account prior local therapy, organ function and underlying medical condition such as inflammatory bowel disease, pulmonary fibrosis, etc.)\n* Patients with prior metastases that have been treated with ablative therapies (e.g. radiotherapy, surgery or radiofrequency ablation) before their current line of systemic therapy, are eligible.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Any medical condition that could, in the opinion of the investigator, preclude radiotherapy or prevent follow-up after radiotherapy.\n* Presence of spinal cord compression\n* Metastatic disease that invades the GI tract (including esophagus, stomach, small or large bowel",{"count":211,"type":20},46,[118],"A registry-based randomized phase II trial. A total of 46 patients with metastatic head and neck cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.",[80,145,33],[216,217,218],"head and neck cancer","metastatic cancer","oligoprogression","2023-12-11",{"date":221,"type":38},"2023-12-12",{"date":223,"type":38},"2021-10-01",{"date":225,"type":20},"2027-12-01",{"name":227,"class":45},"Centre hospitalier de l'Université de Montréal (CHUM)"]